TIA nuclear proteins regulate the alternate splicing of lysyl hydroxylase 2.

Imagen de Mariano Garcia-Blanco
PDF versionPDF version
TítuloTIA nuclear proteins regulate the alternate splicing of lysyl hydroxylase 2.
Publication TypeJournal Article
Year of Publication2009
AutoresYeowell, HN, Walker, LC, Mauger, DM, Seth, P, García-Blanco, MA
JournalJ Invest Dermatol
Volume129
Issue6
Pagination1402-11
Date Published2009 Jun
ISSN1523-1747
Palabras claveAlternative Splicing, Animals, Base Sequence, Gene Expression Regulation, Humans, Mice, Models, Biological, Molecular Sequence Data, Nuclear Proteins, Poly(A)-Binding Proteins, Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase, RNA-Binding Proteins, Sequence Homology, Nucleic Acid
Abstract

Synthesis of collagen, a major component of the extracellular matrix, is increased dramatically in fibrotic conditions such as scleroderma. This overaccumulation of collagen is associated with increased pyridinoline cross-links. These cross-links are derived by the action of the alternatively spliced long form of lysyl hydroxylase 2 (LH2), a collagen telopeptide LH. As LH2 (long) is reported to be overexpressed in scleroderma fibroblasts, the regulation of LH2 splicing suggests an important step in controlling fibrosis. Using an LH2 minigene, we have compared the regulation of the alternative splicing pattern of LH2, both endogenously and in the minigene, by the RNA-binding splicing proteins TIA-1 and TIAL1 (T-cell-restricted intracellular antigens). A decrease in the ratio of LH2 (long) to LH2 (short) was observed in fibroblasts from TIAL1 knockout mice, and in HEK293 cells knocked down for TIA-1 and TIAL1. As a corollary, overexpression of TIA-1/TIAL1 in HEK293 cells resulted in an increase in LH2 (long) minigene transcripts, accompanied by a decrease in LH2 (short). In scleroderma fibroblasts, a double TIA-1/TIAL1 knockdown reduced the ratio of LH2 (long) to LH2 (short) by over fivefold compared to controls. Identification of these TIA regulatory factors therefore suggests a tool to manipulate cellular LH2 levels in scleroderma so that potential intervention therapies may be identified.

DOI10.1038/jid.2008.386
Alternate JournalJ. Invest. Dermatol.
PubMed ID19110540